Literature DB >> 18690998

Cardiovascular drugs and bone.

Lars Rejnmark1.   

Abstract

Cardiovascular diseases are common and occur mainly in the elderly in whom osteoporotic fractures also are very common. Because of this, it is of importance to establish whether drugs used in the treatment of cardiovascular diseases affect bone, in order to minimise any possible adverse effects. In the majority of studies, treatment with thiazide diuretics, statins, digoxin, angiotensin-converting enzyme (ACE)-inhibitors, and organic nitrates have not been associated with harmful effects on bone. On the contrary, treatment with these drugs may improve bone strength but because there is a lack of randomised controlled trials (RCTs) with fracture as a primary outcome measure, these drugs should not be prescribed for fracture prevention. In RCTs, treatment with loop diuretics have been shown to increase plasma levels of parathyroid hormone and decrease bone mineral density. In epidemiological studies, treatment with loop diuretics as well as treatment with amiodarone has been associated with an increased risk of fracture. In view of the conflicting results from published studies, no conclusions can be drawn on potential bone effects of treatment with oral anticoagulants, beta-blockers, and calcium channel blockers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690998     DOI: 10.2174/157488608785699469

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  5 in total

Review 1.  The Key Role of the Blood Supply to Bone.

Authors:  Massimo Marenzana; Timothy R Arnett
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

2.  The ageing endocrine system: Fracture risk after initiation of antihypertensive therapy.

Authors:  Lars Rejnmark
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

3.  Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

Authors:  Douglas A Corley; Ai Kubo; Wei Zhao; Charles Quesenberry
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

4.  Bone density in proton pump inhibitors users: a prospective study.

Authors:  Kamil Ozdil; Resul Kahraman; Abdurrahman Sahin; Turan Calhan; Erdem H Gozden; Umit Akyuz; Burak Erer; Mehmet H Sokmen
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

5.  Alendronate and omeprazole in combination reduce angiogenic and growth signals from osteoblasts.

Authors:  Tormod B Krüger; Bente B Herlofson; Aina M Lian; Unni Syversen; Janne E Reseland
Journal:  Bone Rep       Date:  2021-01-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.